All AbMole products are for research use only, cannot be used for human consumption.
MK-4827 (Niraparib) is an oral potent, selective PARP-1 and PARP-2 inhibitor currently in phase I clinical trials for cancer treatment. MK-4827 shows excellent PARP 1 and 2 inhibition with IC(50) = 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with EC(50) = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC(50) in the 10-100 nM range. MK-4827 reduced PAR levels in tumors by 1 h after administration which persisted for up to 24 h. MK-4827 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer. In addition, MK-4827 strongly enhances the effect of radiation on a variety of human tumor xenografts, both p53 wild type and p53 mutant.
Cancers (Basel). 2026 Feb 09;18.
PARP Inhibitors Combined with Abiraterone Overcome Resistance in Metastatic Castration-Resistant Prostate Cancer Independently of Androgen Receptor
Niraparib (MK-4827) purchased from AbMole
Sci Rep. 2023 Feb 27;13(1):3334.
Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer
Niraparib (MK-4827) purchased from AbMole
Nat Commun. 2019 Jun 11;10(1):2556.
Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
Niraparib (MK-4827) purchased from AbMole
 |
Source | Oncotarget (2017). Figure 3. MK-4827 |
| Method | Western blotting | |
| Cell Lines | J45.01 cells | |
| Concentrations | - | |
| Incubation Time | 48 hrs | |
| Results | Similar analysis for DNMT1 showed increased levels of DNMT1 in the chromatin-bound fraction from cells exposed to [DAC+Rom+Npb] compared with cells exposed to [DAC+Rom]; the DNMT1 ratio was 0.25:1 ([DAC+Rom+Npb]:[DAC+Rom]) in the soluble extracts and 2.09:1 in the chromatin-bound fractions |
| Cell Experiment | |
|---|---|
| Cell lines | |
| Preparation method | |
| Concentrations | |
| Incubation time | |
| Animal Experiment | |
|---|---|
| Animal models | Female nude mice (Ncr Nu/Nu) with solitary tumor xenografts |
| Formulation | suspended in 0.5% HPMC in deionized water, mixed for 24 h |
| Dosages | 25 or 50 mg/kg |
| Administration | orally gavage |
| Molecular Weight | 320.39 |
| Formula | C19H20N4O |
| CAS Number | 1038915-60-4 |
| Solubility (25°C) | DMSO ≥ 20 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related PARP Products |
|---|
| ABT-888
ABT-888 (Veliparib) is a potent inhibitor of PARP-1 and PARP-2 with Ki values of 5.2nM and 2.9nM respectively. |
| AG-014699 phosphate
AG-014699 (PF-01367338, Rucaparib) is a PARP inhibitor with a Ki of 1.4 nM. |
| AG14361
AG14361 is a novel poly (ADP-ribose) polymerase-1 inhibitor with a GI50 of 10.9 µM. |
| AZD2281 (Olaparib)
AZD 2281 (Olaparib, KU-0059436) is a potent PARP (poly ADP-ribose polymerase) inhibitorwith IC50 of 5 and 1 nM for PARP-1and PARP-2 respectively. Olaparib is an autophagy and mitophagy activator. |
| Talazoparib
Talazoparib (BMN-673) is a highly potent, orally active PARP1/2 inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with Kis of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
